• Results for the First Quarter 2020

  29. Apr 2020

  Sales for the quarter ended at a record high MNOK 103.1 (MNOK 88.7), a 16.2% increase.This was driven by strong growth in capital sales of systems in Japan after regulatory approval of MiraQ™. Read the…

  Read more

• Annual Report 2019

  27. Mar 2020

  We have now achieved a market penetration of 23% in USA, measured as the share of bypass procedures done with Medistim’s devices. Our position in Asia and Europe is also strengthened, through increased sales and…

  Read more

• The REQUEST study is now published

  24. Mar 2020

  The REQUEST study is a multicenter, prospective study among 7 international centers performing coronary artery bypass grafting procedures.  The primary endpoint was any change in the planned surgical procedure. Major secondary endpoints consisted of the…

  Read more

• Results for Fourth Quarter and Preliminary Results for Medistim for 2019

  28. Feb 2020

  Sales for the quarter ended at MNOK 95.7 (MNOK 97.9), while sales for 2019 ended at MNOK 363.7 (MNOK 325.9), a growth of 11.6%. Q4 2019 PresentationQ4 and preliminary year-end financials 2019

  Read more

• Investor Presentation, March 3

  25. Feb 2020

  Medistim’s CEO Kari E. Krogstad will hold an investor presentation at the Carnegie Healthcare Seminar 2020 in Stockholm, Sweden. Date: Tuesday March 3, 2020 Venue: Regeringsgatan 56. 103 38 Stockholm For more information about this…

  Read more

• Results for the Third Quarter 2019

  25. Oct 2019

  Sales ended at MNOK 85.5 for the quarter (MNOK 77.6), a 10.2 %  growth. Sales as of September increased by 17.6 % and ended at MOK 268.1(MNOK 228.0). Read the full report and presentation below.…

  Read more

• Medistim has received clearance for sale of MiraQ™ in Japan

  27. Sep 2019

  Medistim announces that they have received confirmation from its distributor in Japan that its newest product MiraQ™ is now approved for sale. MiraQ is Medistim's newest generation of products for quality assurance within vascular and…

  Read more

• Results for the Second Quarter and First Half 2019

  20. Aug 2019

  Q2 2019 is the third consecutive quarter with strong growth in both sales revenues and EBIT; 23.1 % and 70.4 % respectively.  Read the full report and presentation below. Medistim Q2 19 presentation 2.quarter 2019

  Read more

• Results for the First Quarter 2019

  25. Apr 2019

  Sales in the first quarter amounted to MNOK 88.7 (MNOK 74.1), a 19.7 % growth. Of the MNOK 14.6 in sales growth, MNOK 11.6 was from the US, where the sales increase in NOK was…

  Read more

• Annual Report 2018

  15. Mar 2019

  During 2018, we reached an important milestone when the final results from the 1000 patients prospective, multi-center registry study REQUEST was presented. In this study, some of the best cardiac centers in Europe, Canada, and…

  Read more